Home › Compare › MURSF vs ABBV
MURSF yields 8000.00% · ABBV yields 3.06%● Live data
📍 MURSF pulled ahead of the other in Year 1
Combined, MURSF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MURSF + ABBV for your $10,000?
Murray & Roberts Holdings Limited operates as a multinational engineering and construction company. It operates through Power, Industrial & Water; Mining; Energy, Resources & Infrastructure; Corporate & Properties segments. The company provides development, engineering, procurement, construction, operations, and maintenance solutions to the power, water, oil and gas, petrochemical, resources, industrial, and transmission and distribution markets primarily in South Africa and sub-Saharan Africa. It offers services for mining platforms, including feasibility studies, specialist engineering, vertical and decline shaft construction, mine development, and specialist mining services, such as raise boring and grouting, underground construction, and material handling solutions, as well as contract mining for projects in Australia, Indonesia, Mongolia, Kazakhstan, South Africa, sub-Saharan Africa, Canada, the United States, and Mexico. The company provides engineering and contracting services for energy, and resources and infrastructure markets, such as engineering, procurement, construction, commissioning, operations, and maintenance services; and operates under the Clough brand. Murray & Roberts Holdings Limited was founded in 1902 and is headquartered in Bedfordview, South Africa.
Full MURSF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.